UNIVERSITY OF RUSE "ANGEL KANCHEV"
UNION OF SCIENTISTS - RUSE

Proceedings 2024
Faculty of Public Health and Health CareBook 8.4 · Medical and Clinical Diagnostic Activities

FRI-2G.309-1-MCDA-07

NEWS IN IMMUNOMODULATION

Language: BGPages: 38-43

Cite this paper

Assoc. Prof. Svilen Dosev, PhD

Department of Medical Clinical and Diagnostical Activities Univesity of Ruse “Angel Kanchev”

E-mail: dr.dosev@gmail.com

Chief. Assist. Kina Velcheva, PhD

Department of Health Care Univesity of Ruse “Angel Kanchev”

ORCID: 0000-0003-2654-5247

E-mail: kvelcheva@uni-ruse.bg

Abstract

The challenge in the diagnosis of viral infections is the difficulty in the treatment of viral diseases, especially those with a recurrent nature, associated with the variety of etiological agents and the lack of effective countermeasures. A key role of immunity in all types of infections, including viral ones, is the decisive role of the resistance forces to successfully deal with microorganisms (Kaczmarczyk, D., Zagacki, D., & Morawiec-Sztandera, A., 2021). Clinical evidence in the treatment of viral infections with Inosine Pranobex is effective in reducing flu-like symptoms and duration of illness. It is effective in treating individuals with confirmed acute respiratory viral infections. A significantly lower % of patients receiving Inosine Pranobex had flu-like symptoms after 9 days compared to those in the placebo group (Beran, J., Šalapová, E., & Špajdel, M., 2016). According to the World Bank, antibacterial resistance could lead to 1 trillion US dollars in additional health care costs by 2050 and 1 - 3.4 trillion US dollars in gross domestic product (GDP) losses annually by 2030. treatment (Diku, S., 2024).WHO recommends "antibiotic-free treatment" - in low-risk patients with mild infections that do not require antibiotic treatment (Luritq, S., 2011).

Keywords

Antibacterial, Resistance, Healthcare, Infections

REFERENCES

  • Bekesi, G., Tsang, H., Wallace, I., & Roboz, P. (1987). Immunorestorative properties of isoprinosine in the treatment of patients at high risk of developing ARC or AIDS. J. Clin. Lab. Immunol, 24, 155-61.
  • Beran, J. (2016). Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. Isoprinosine Study (EWO ISO-2014/1) BMC Infect Dis. 2016;16(1):648. Published 2016 Nov 7. doi:10.1186/s12879-016-1965-5.
  • Beran, J., Šalapová, E., & Špajdel, M. (2016). Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. Isoprinosine Study (EWO ISO-2014/1) BMC Infect Dis. 2016;16(1):648. Published 2016 Nov 7. doi:10.1186/s12879- 016-1965-5).
  • Carthy, M., Lin, D., & Soga, T. (2020). Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression. Eur. J. Immunol, 50, 130-137.
  • Diku, S. (2024). Drug-Resistant Infections: A Threat to Our Economic future and inhibits monocyte chemiluminescence in vitro. APMIS, 102, 249-254. https://www.worldbank.org/en/topic/health/publication/drug-resistant-infections-a-threat-to-our-economic-future).
  • Goêbiowska-Wawrzyniak, M. (2004). The study on therapeutic efficacy of inosine pranobex in children, Pol. J. Food Nutr. Sci., Vol. 13/54, SI 2, pp. 33-36.
  • Hadden, W. (1993). Immunostimulans. Immunology Today,14, 275-280.267-271 (in Polish).
  • Kaczmarczyk, D., Zagacki, D., & Morawiec-Sztandera, A. (2021). Upper respiratory tract infection in children - immunostimulating treatment. Journal of Education, Health and Sport;11(9):80-89. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2021.11.09.011.
  • Luritq, S. (2011). The WHO AWaRe (Access, Watch, Reserve) antibiotic book. The Lancet; 399(10325): P629-655. DOI: https://doi.org/10.1016/S0140-6736(21)02724-0).
  • Marton, A., Pacher, P., Murthy, G., Nemeth, H., Hasko, G., & Szabo, C. (2001). Anti- inflammatory effects of inosine in human monocytes, neutrophilis and epithelial cells in vitro. Int. J. Mol. Med., 8, 617-621.
  • Mulcahy, G., Quinn, PJ., & Hannan, J. (1991). The effect of Isoprinosine and levamisole on factors relevant to protection of calves against respiratory disease. J. Vet. Pharmacol. Therap., 14, 156-169.
  • Naess, A., & Albrektsen, G. (1994). Isoprinosine stimulates granulocyte chemiluminescence
  • Ohnishi, H., Kosuzume, H., & Inaba, H. (1982). Mechanism of host defense suppression induced by viral infection:mode of action of inosiplex as an antiviral agents. Infect Immun, 38 (1): 243-50)
  • Petrova, M., Jelev, D., Ivanova, A., & Krastev, Z. (2010). Isoprinosine affects serum cytokine levels in healthy adults. J Interferon Cytokine Res, 30: 223-8.
  • Siwicki, K., & Skopiñska-Róewska, E. (2003). Immunomodulacja- aktualny stan wiedzy in: Rola immunomodulatorów pochodzenia naturalnego w zapobieganiu i leczeniu chorób (ed. E. Skopiñska-Ró¿ewska, A.K.Siwicki). Medyk, W-wa, 7-14 (in Polish).
  • Siwiñska, G., & Piekarczyk, A. (2004). Clinical, Pharmacological and Toxicological Expert Report on Groprinosin, IMiD, Warszawa.
  • Wawrzyniak, M. (2004). The study on therapeutic efficacy of inosine pranobex in children, Pol. J. Food Nutr. Sci.,Vol. 13/54, SI 2, pp. 33-36.
  • World Health Organization. (2022). Guidelines for the clinical management of severe illness from influenza virus infections. World Health Organization. https://apps.who.int/iris/handle/10665/352453. License: CC BY-NC-SA 3.0 IGO.
  • Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet; 399(10325): P629-655. DOI: https://doi.org/10.1016/S0140-6736(21)02724-0).
Open paper as PDF